Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)

Inclusion Criteria:

• Male or female patients aged between 18 to 65 years.

• Have an acute illness (less than or equal to 7 days duration) with any of thefollowing signs and symptoms consistent with a lower respiratory tract infection (new or worsening):

1. Fever (body temperature > 38.0 °C (100.4 °F) measured orally)

2. Shortness of breath

3. New onset or increased cough with or without sputum production.

4. Chest pain.

• Have radiographically documented bacterial pneumonia:

1. Infiltrates in a unilateral, lobar distribution

2. Diffuse opacities or white condensed area

3. The alveoli fill with white inflammatory fluid

Exclusion Criteria:

• Patients with severe pneumonia (Clinical & Radiological Assessment)

• Patients with suspicion of viral pneumonia (bilateral, patchy opacities, etc., inchest radiography.)

• Patients with suspicion of nosocomial pneumonia, aspiration pneumonia, etc.

• History of hypersensitivity, known or suspected contraindications, or intolerance toany of the study drugs.

• Intake of an antibiotic within the last 48 hours before study admission.

• History of hospitalization within the last 28 days.

• Patients in pregnancy and lactational state.

• Patients with Renal impairment (screening eGFR < 30mL/min).

• Significant hepatic impairment (Alanine aminotransferase > three times the upperlimit of normal).

• Serious diseases that affect the immune system, such as Acquired ImmunodeficiencySyndrome (AIDS), cancer, etc.

• Patients who are taking steroid medications, at least 20 mg daily dose ofprednisolone (or equivalent doses of other glucocorticoids).

• Patients who are accepting chemotherapy or anti-cancer therapy or plan to receivesuch treatment during the trial or six months prior to enrollment.

• Had epilepsy, stroke, or other central nervous system disorders or uncontrolledpsychiatric history.